Mineralys TherapeuticsMLYS
About: Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
Employees: 28
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
1,042% more call options, than puts
Call options by funds: $217K | Put options by funds: $19K
269% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 13
20% more funds holding in top 10
Funds holding in top 10: 5 [Q1] → 6 (+1) [Q2]
17% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 12
4.48% more ownership
Funds ownership: 86.47% [Q1] → 90.95% (+4.48%) [Q2]
2% more funds holding
Funds holding: 92 [Q1] → 94 (+2) [Q2]
5% less capital invested
Capital invested by funds: $554M [Q1] → $528M (-$25.7M) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Matthew Caufield 65% 1-year accuracy 15 / 23 met price target | 124%upside $30 | Buy Reiterated | 12 Nov 2024 |
HC Wainwright & Co. Matthew Caufield 65% 1-year accuracy 15 / 23 met price target | 124%upside $30 | Buy Reiterated | 31 Oct 2024 |
HC Wainwright & Co. Matthew Caufield 65% 1-year accuracy 15 / 23 met price target | 124%upside $30 | Buy Reiterated | 15 Aug 2024 |
Financial journalist opinion
Based on 17 articles about MLYS published over the past 30 days
